Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59946 | 0.91 | MAP4K4 (0.39) | MAP4K4NR1H2EGLN2RIPK1MTOR | |
| SCHEMBL60338 | 0.84 | GRM1 (0.46) | — | |
| SCHEMBL28902622 | 0.83 | RIPK1 (0.37) | MAP4K4RIPK1CSNK2A2CSNK2A1 | |
| SCHEMBL14313009 | 0.83 | TNK2 (0.42) | MAP4K4 | |
| SCHEMBL16021415 | 0.82 | DGAT2 (0.35) | NR1H2EGLN2RIPK1DGAT2 | |
| SCHEMBL14327042 | 0.79 | BTK (0.43) | MAP4K4NR1H2EGLN2RIPK1SMARCA2 | |
| SCHEMBL14312660 | 0.79 | NR1H2 (0.57) | MAP4K4NR1H2EGLN2RIPK1ESR2 | |
| SCHEMBL14898489 | 0.78 | MAP4K4 (0.36) | MAP4K4EGLN2RIPK1SMARCA2SMARCA4 | |
| SCHEMBL5080489 | 0.78 | EGLN2 (0.55) | MAP4K4EGLN2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL21199519 | 0.77 | SRC (0.36) | MAP4K4RIPK1SRCEGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113336760-B | Substituted amide derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113493439-B | Substituted acrylamide derivative, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | MAP4K4 1324/4885NR1H2 3281/4885EGLN2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.